73 completed, 10 terminated, 6 unknown, 3 not yet recruiting. 95 Phase 3, 6 Phase 2.
Follow Urinary Bladder, Overactive: new trials by email Literature Review of Urinary Bladder, Overactive trials Research Report on Urinary Bladder, Overactive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Non-invasive Saphenous Nerve Stimulation Therapy for Overactive Bladder Wearable neurostimulation system for saphenous nerve stimulation, tolterodine tartrate 4 mg extended release - Overactive Bladder (OAB) | Phase 3 | Not yet recruiting | NinaMED Pty Ltd | 290 | 2026-09-10 | 2026-08-24 |
| Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women solifenacin combined with gabapentin, solifenacin monotherapy - Overactive Bladder | Phase 3 | Not yet recruiting | Mansoura University | 60 | 2026-02-01 | 2026-02-24 |
| The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial Mirabegron 25mg, Solifenacin 5 mg, Tolterodine 4 mg - Urinary Bladder, Overactive | Phase 3 | Not yet recruiting | Far Eastern Memorial Hospital | 220 | 2025-08-07 | 2025-08-11 |
| Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry) Solifenacin, Mirabegron - Urinary Incontinence in Children | Phase 3 | Recruiting | University of Aarhus | 236 | 2024-06-27 | 2026-06-08 |
| Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms OnabotulinumtoxinA - Urinary Incontinence, Overactive Bladder Syndrome | Phase 2 / Phase 3 | Active not recruiting | Northwestern University | 66 | 2023-07-13 | 2026-10-13 |
| The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder Alkalinized Lidocaine, Placebo Sodium Chloride 0.9% Inj - Urge Incontinence, Overactive Bladder | Phase 3 | Unknown | Herlev and Gentofte Hospital | 50 | 2022-09-12 | 2022-09-22 |
| A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder DA-8010 Placebo, DA-8010 2.5mg, DA-8010 5mg - Overactive Bladder | Phase 3 | Completed | Dong-A ST Co., Ltd. | 607 | 2022-05-12 | 2024-06-26 |
| A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) Mirabegron, Placebo - Overactive Bladder (OAB), Pharmacokinetics of Mirabegron | Phase 3 | Terminated | Astellas Pharma Global Development, Inc. | 26 | 2021-03-15 | 2024-11-14 |
| To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder JLP-2002 A mg, Placebo - Overactive Bladder | Phase 3 | Completed | Jeil Pharmaceutical Co., Ltd. | 210 | 2020-05-21 | 2022-01-28 |
| Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia Vibegron - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 276 | 2019-09-19 | 2024-08-21 |
| Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder Neuronox, Placebo - Overactive Bladder | Phase 3 | Unknown | Medy-Tox | 216 | 2019-08-23 | 2020-07-28 |
| Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) Vibegron, Placebo - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 1105 | 2019-03-26 | 2024-08-07 |
| An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). Vibegron, placebos, Tolterodine Tartrate ER - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 506 | 2018-06-14 | 2021-03-18 |
| A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) vibegron, Vibegron placebo, Tolterodine Tartrate ER - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 1530 | 2018-03-26 | 2021-03-04 |
| Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease solifenacin, Pelvic floor muscle exercise-based behavioral therapy - Overactive Bladder, Parkinson Disease | Phase 3 | Completed | VA Office of Research and Development | 77 | 2018-03-01 | 2024-09-24 |
| Low-level Light Therapy for Overactive Bladder and Urinary Incontinence Low-level light therapy, Placebo - Overactive Bladder, Urinary Incontinence | Phase 3 | Unknown | Seoul National University Hospital | 120 | 2016-12-01 | 2016-12-07 |
| Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity GSK1358820, Placebo - Urinary Bladder, Overactive | Phase 3 | Completed | GlaxoSmithKline | 21 | 2016-10-11 | 2021-07-14 |
| Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder GSK1358820, Placebo, Antibiotic therapy - Urinary Bladder, Overactive | Phase 3 | Completed | GlaxoSmithKline | 250 | 2016-08-10 | 2020-11-27 |
| Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder. Uritos®, Urotol® - Overactive Bladder | Phase 3 | Completed | R-Pharm | 300 | 2016-07-18 | 2019-05-21 |
| Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 Botulinum toxin type A, Placebo - Urinary Incontinence, Overactive Bladder | Phase 3 | Terminated | Ipsen | 258 | 2016-07-08 | 2022-09-28 |
Showing 20 of 95. Sign in to see all of them.
Urinary Incontinence (32) · Urinary Incontinence, Urge (18) · Urologic Diseases (6) · Nocturia (5) · Lower Urinary Tract Symptoms (4) · Prostatic Hyperplasia (2) · Urinary Bladder Diseases (2) · Diurnal Enuresis (1) · Hematuria (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Male Urogenital Diseases (1) · Multiple Sclerosis (1) · Pain, Procedural (1) · Parkinson Disease (1)
Female Urogenital Diseases (95) · Female Urogenital Diseases and Pregnancy Complications (95) · Pathological Conditions, Signs and Symptoms (95) · Signs and Symptoms (95) · Urogenital Diseases (95) · Urological Manifestations (95) · Male Urogenital Diseases (94) · Urinary Bladder Diseases (93) · Lower Urinary Tract Symptoms (91) · Urologic Diseases (89) · Urination Disorders (42) · Urinary Incontinence (10) · Nervous System Diseases (4) · Central Nervous System Diseases (2) · Genital Diseases (2)
Solifenacin Succinate (21) · Botulinum Toxins, Type A (19) · Tolterodine Tartrate (19) · mirabegron (17) · fesoterodine (8) · Saline Solution (7) · N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (4) · oxybutynin (4) · propiverine (4) · darifenacin (3) · imidafenacin (3) · Gabapentin (2) · abobotulinumtoxinA (2) · ritobegron ethyl (2) · Anti-Infective Agents (1)
Astellas Pharma Inc (14) · Allergan (8) · Pfizer (7) · Astellas Pharma Europe B.V. (4) · Urovant Sciences GmbH (4) · APOGEPHA Arzneimittel GmbH (2) · Astellas Pharma Europe Ltd. (2) · CHU de Quebec-Universite Laval (2) · Duramed Research (2) · GlaxoSmithKline (2) · Ipsen (2) · Kissei Pharmaceutical Co., Ltd. (2) · Novartis (2) · Ono Pharmaceutical Co., Ltd. (2) · Stéphane Bolduc (2)
United States (50) · Canada (23) · Poland (21) · Belgium (20) · Germany (19) · United Kingdom (19) · Czechia (17) · Russia (17) · South Korea (17) · Spain (15) · Ukraine (15) · Denmark (13) · France (13) · Hungary (13) · Italy (13)
Yasuhiro Omori (2) · Alexis Te (1) · Amy Krambeck, MD (1) · Anthony Visco, MD (1)
PMID 37160401, PMID 24246044, PMID 35881009, PMID 21293089, PMID 24754838, PMID 25288099, PMID 26231052, PMID 35400537, PMID 37811598, PMID 18499184, PMID 18502028, PMID 18584946, PMID 18663723, PMID 19143854, PMID 19233423, PMID 19348029, PMID 20121659, PMID 20707767, PMID 20723260, PMID 20829244, PMID 21428726, PMID 21798658, PMID 22008247, PMID 22092152, PMID 22503020, PMID 22965657, PMID 23036134, PMID 23218404, PMID 23448285, PMID 23608668, PMID 23769122, PMID 23892704, PMID 26516810, PMID 26876327, PMID 26965560, PMID 27564385, PMID 27687820, PMID 28150436, PMID 28916436, PMID 29866467, PMID 31930360, PMID 32239291, PMID 32665528, PMID 33231929, PMID 33332699, PMID 33356445, PMID 33469832, PMID 33620895, PMID 34292493, PMID 34921665
2015 (2), 2017 (2), 2018 (2), 2008 (1), 2014 (1), 2016 (1), R03AG042335 (1), U01HD041249 (1), U10HD041250 (1), U10HD041261 (1), U10HD041267 (1), U10HD054136 (1), U10HD054214 (1), U10HD054215 (1), U10HD054241 (1)